Beyond statins: new lipid lowering strategies to reduce cardiovascular risk

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Biochemistry

Background:

• Statins are primary therapy for lowering LDL-Cholesterol (LDL-C), crucial for preventing atherosclerotic vascular disease.
• A significant patient subset remains at high risk despite statin use, necessitating advanced lipid-lowering strategies.

Purpose of the Study:

• To review novel therapeutic approaches for further LDL-C reduction.
• To evaluate agents for patients with high residual risk, severe hypercholesterolemia, or statin intolerance.

Main Methods:

• Review of four novel drug classes: PCSK9, apoB, CETP, and MTP inhibitors.
• Analysis of current clinical use and trial data for these emerging therapies.

Main Results:

• ApoB and MTP inhibitors (Mipomersen, Lomitapide) are approved for homozygous familial hypercholesterolemia.
• Ongoing trials for CETP and PCSK9 inhibitors show promise for broader application.

Conclusions:

• Novel inhibitors targeting PCSK9, apoB, CETP, and MTP represent significant advancements in lipid management.
• These agents hold potential for expanded use in high-risk cardiovascular populations, complementing statin therapy.